NCT03900429: An ongoing trial by Madrigal Pharmaceuticals, Inc.
This trial is completed, but has been granted a delay in reporting its results.
It must report results 5 years, 1 month from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03900429 |
|---|---|
| Title | A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (Resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 28, 2019 |
| Completion date | Jan. 31, 2028 |
| Required reporting date | Jan. 31, 2031, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |